A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.
Men with advanced prostate cancer typically receive hormonal therapy to reduce the level of androgens, or male hormones, in their bodies. Although hormone therapy alone will not cure prostate cancer, lowering androgen levels can reduce prostate tumors size or stall their growth.
The original RTOG 9202 trial (Hanks 2003) evaluated the potential benefits of long-term adjuvant androgen deprivation (LTAD) for two years after initial androgen deprivation, when compared to short-term (initial) androgen therapy (STAD) in mostly high-risk prostate cancer patients receiving external beam radiation therapy (EBRT). Because some intermediate-risk prostate cancer patients were included in the study, a current analysis was conducted to determine if patients in the intermediate-risk subset experienced an additional survival benefit with LTAD.
Researchers reviewed all patients enrolled in RTOG 9202 categorized with intermediate-risk prostate cancer with T2 disease (tumor confined to the prostate), a Prostate Specific Antigen (PSA) of < 10 and a Gleason Score of 7; or, who were immediate-risk prostate cancer patients with T2 disease, PSA of 10-20 and a Gleason Score < 7. A total of 133 patients were analyzed. The LTAD group consisted of 59 patients, and the STAD group consisted of 74 patients. Statistical analysis was used to determine Overall Survival (OS), Disease Specific Survival (DSS) and PSA Failure rates (PSAF), and the median follow-up was more than 11 years. There was no statistical difference in OS with 10-year estimates of 61 percent for the STAD group and 65 percent for the LTAD group. DSS was found to be 96 percent in both groups. PSAF occurred in 38 patients in the STAD group and in 33 in the LTAD group. Ten-year PSAF rates were 53 percent for the STAD group and 55 percent for the LTAD group (p=.99).
"Most clinicians have felt that 'more was better' when it came to blocking testosterone in prostate cancer patients, however, results for the specific endpoints we focused on, OS and DSS, indicate that this was clearly not the case," said Amin Mirhadi, MD, lead author of the study and a radiation oncologist at Cedars-Sinai Medical Center in Los Angeles. "This data supports administering less treatment, which will result in fewer side effects and reduce patients' overall health care costs."
Explore further: Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
More information: The abstract, "Effect of Long-Term Hormonal Therapy (vs. Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate Risk Prostate Cancer Patients Treated on RTOG 9202," will be presented in detail in a scientific session at ASTRO's Annual Meeting at 10:45 a.m. Eastern time, on Monday, September 23, 2013.
Medical Xpress on facebook
Related Stories
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
1 hour ago
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate ...
Implications of very low risk prostate cancer assessed
Sep 20, 2013
(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...
Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer
Jul 13, 2011
Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared ...
Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer
Nov 02, 2009
Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation ...
On-and-off approach to prostate cancer treatment may compromise survival
Apr 03, 2013
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
Recommended for you
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
1 hour ago
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate ...
Two-item questionnaire proves to be a valid depression screening tool for radiation therapy patients
1 hour ago
Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation ...
Avoiding specific region of brain during whole-brain radiotherapy prevents memory loss
1 hour ago
Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according ...
Patient-reported outcomes provide valuable insight regarding quality of life for patients with NSCLC
1 hour ago
An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared ...
ASTRO/AUA joint guideline for RT after prostatectomy highlighted at ASTRO Annual Meeting
2 hours ago
The American Society for Radiation Oncology (ASTRO) will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO's 55th Annual Meeting, September 22-25, 2013, ...
Adult cancer patients younger than 50 with limited brain mets have improved OS after SRS alone
2 hours ago
When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to ...
User comments
© Medical Xpress 2011-2013, Phys.org network
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.
Men with advanced prostate cancer typically receive hormonal therapy to reduce the level of androgens, or male hormones, in their bodies. Although hormone therapy alone will not cure prostate cancer, lowering androgen levels can reduce prostate tumors size or stall their growth.
The original RTOG 9202 trial (Hanks 2003) evaluated the potential benefits of long-term adjuvant androgen deprivation (LTAD) for two years after initial androgen deprivation, when compared to short-term (initial) androgen therapy (STAD) in mostly high-risk prostate cancer patients receiving external beam radiation therapy (EBRT). Because some intermediate-risk prostate cancer patients were included in the study, a current analysis was conducted to determine if patients in the intermediate-risk subset experienced an additional survival benefit with LTAD.
Researchers reviewed all patients enrolled in RTOG 9202 categorized with intermediate-risk prostate cancer with T2 disease (tumor confined to the prostate), a Prostate Specific Antigen (PSA) of < 10 and a Gleason Score of 7; or, who were immediate-risk prostate cancer patients with T2 disease, PSA of 10-20 and a Gleason Score < 7. A total of 133 patients were analyzed. The LTAD group consisted of 59 patients, and the STAD group consisted of 74 patients. Statistical analysis was used to determine Overall Survival (OS), Disease Specific Survival (DSS) and PSA Failure rates (PSAF), and the median follow-up was more than 11 years. There was no statistical difference in OS with 10-year estimates of 61 percent for the STAD group and 65 percent for the LTAD group. DSS was found to be 96 percent in both groups. PSAF occurred in 38 patients in the STAD group and in 33 in the LTAD group. Ten-year PSAF rates were 53 percent for the STAD group and 55 percent for the LTAD group (p=.99).
"Most clinicians have felt that 'more was better' when it came to blocking testosterone in prostate cancer patients, however, results for the specific endpoints we focused on, OS and DSS, indicate that this was clearly not the case," said Amin Mirhadi, MD, lead author of the study and a radiation oncologist at Cedars-Sinai Medical Center in Los Angeles. "This data supports administering less treatment, which will result in fewer side effects and reduce patients' overall health care costs."
Explore further: Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
More information: The abstract, "Effect of Long-Term Hormonal Therapy (vs. Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate Risk Prostate Cancer Patients Treated on RTOG 9202," will be presented in detail in a scientific session at ASTRO's Annual Meeting at 10:45 a.m. Eastern time, on Monday, September 23, 2013.
Medical Xpress on facebook
Related Stories
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
1 hour ago
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate ...
Implications of very low risk prostate cancer assessed
Sep 20, 2013
(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...
Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer
Jul 13, 2011
Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared ...
Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer
Nov 02, 2009
Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation ...
On-and-off approach to prostate cancer treatment may compromise survival
Apr 03, 2013
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
Recommended for you
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
1 hour ago
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate ...
Two-item questionnaire proves to be a valid depression screening tool for radiation therapy patients
1 hour ago
Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation ...
Avoiding specific region of brain during whole-brain radiotherapy prevents memory loss
1 hour ago
Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according ...
Patient-reported outcomes provide valuable insight regarding quality of life for patients with NSCLC
1 hour ago
An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared ...
ASTRO/AUA joint guideline for RT after prostatectomy highlighted at ASTRO Annual Meeting
2 hours ago
The American Society for Radiation Oncology (ASTRO) will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO's 55th Annual Meeting, September 22-25, 2013, ...
Adult cancer patients younger than 50 with limited brain mets have improved OS after SRS alone
2 hours ago
When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment